MediciNova Inc. (MNOV)
-NasdaqGM | Prev Close: | 2.57 |
|---|
| Open: | N/A |
|---|
| Bid: | 2.50 x 3000 |
|---|
| Ask: | 2.93 x 1000 |
|---|
| 1y Target Est: | 6.00 |
|---|
| Beta: | 1.22 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 1.49 - 4.70 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 73,189 |
|---|
| Market Cap: | 50.54M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.56 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: MediciNova: UCLA presents data on MediciNova's MN-166 in methamphetamine addicitionBriefing.com(Tue, Jun 18)
- UCLA Presents Data on MediciNova's MN-166 in Methamphetamine Addiction at the 75th Annual Meeting of the College on Problems of Drug DependenceGlobeNewswire(Tue, Jun 18)
- MEDICINOVA INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of SecuEDGAR Online(Mon, Jun 17)
- MEDICINOVA INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; TrEDGAR Online(Fri, Jun 7)
- MEDICINOVA INC FinancialsEDGAR Online Financials(Tue, May 14)
- Monday Sector Leaders: Biotechnology, Drugsat Forbes(Mon, May 13)
- MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiesEDGAR Online(Thu, May 9)
- MEDICINOVA INC Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Thu, May 9)
- MediciNova Reports First Quarter 2013 ResultsGlobeNewswire(Wed, May 8)
- MEDICINOVA INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- MedicNova enters into 6M equity distribution agreement with Macquarieat theflyonthewall.com(Thu, Apr 18)
- MEDICINOVA INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Wed, Apr 17)
- MEDICINOVA INC Files SEC form 8-K, Other EventsEDGAR Online(Wed, Apr 17)
- MEDICINOVA INC Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Fri, Mar 29)
- MediciNova Reports Fourth Quarter and Full Year 2012 ResultsGlobeNewswire(Thu, Mar 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 82.22 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.54 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | -0.23 |
|---|
Business Summary
MediciNova, Inc., a development stage biopharmaceutical company, focuses on acquiring and developing small molecule therapeutics for the treatment of serious diseases for the United States market.
View More 
0.91%